Amyloidose-Zentrum - Universitätsklinikum Heidelberg | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to Places / Academic & Health Care Centers
Amyloidose-Zentrum – Universitätsklinikum Heidelberg

Amyloidose-Zentrum – Universitätsklinikum Heidelberg

Im Neuenheimer field 672
Heidelberg, Germany
Email   Phone   Web  
The Amyloidose-Zentrum was founded at the Universitätsklinikum Heidelberg in October 2008. The main objectives of the Amyloidose-Zentrum are interdisciplinary diagnosis, counselling, and treatment of patients with amyloidosis diseases. 
 
A group of experts from various fields has come together at the Amyloidose-Zentrum – Universitätsklinikum Heidelberg to collaboratively diagnose and treat the rare medical condition – amyloidosis. We use our extensive knowledge on an interdisciplinary basis to provide the best possible treatment for our patients.
 
Medical specialists from departments like anesthesiology, surgery, gastroenterology, hematology/oncology, cardiac surgery, human genetics, cardiology, nephrology, neurology, and rheumatology, etc work collaboratively at the Amyloidose-Zentrum – Universitätsklinikum Heidelberg. The success of this close cooperation is reflected by the continuously increasing number of patients from all parts of Germany treated at Universitätsklinikum Heidelberg, which currently treats more than 1500 patients with systemic amyloidosis, the largest group of such patients in the country. Treatment is provided in different departments of the medical center, depending on the treatment focus.
 

After a specific diagnosis has been established regarding the type of amyloidosis, the medical specialists at our Amyloidose-Zentrum will recommend an individual, interdisciplinary treatment strategy that matches the type and extent of the disorder. The strategy will be aimed at the cause of the disorder and will attempt to prevent additional amyloid being deposited. The therapy must start as early as possible, as amyloid that has already been deposited cannot be removed from the tissues.

The team includes healthcare professionals in the following areas:

Hematology and Oncology:
Stefan Schonland

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close